ensitrelvir

SARS-CoV-2 3CL protease inhibitor

Also Known As:

(6E)-6-((6-chloro-2-methyl-2H-indazol-5-yl)imino)dihydro-3-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1-((2,4,5-trifluorophenyl)methyl)-1,3,5-triazine-2,4(1H,3H)-dione; S-217622; S217622

Networked: 25 relevant articles (4 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - ensitrelvir: 25
    - Pyrazoles: 61
      - Indazoles: 179
        ensitrelvir: 25
  - Triazines: 306
    - ensitrelvir: 25
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indazoles: 179
      - ensitrelvir: 25

Experts

1.	Ando, Shigeru: 1 article (12/2022)
2.	Kasamatsu, Koji: 1 article (12/2022)
3.	Kato, Teruhisa: 1 article (12/2022)
4.	Kawashima, Sho: 1 article (12/2022)
5.	Kouki, Kensuke: 1 article (12/2022)
6.	Maruyama, Yuki: 1 article (12/2022)
7.	Mizutare, Tohru: 1 article (12/2022)
8.	Nakahara, Kenji: 1 article (12/2022)
9.	Nakahashi, Atsufumi: 1 article (12/2022)
10.	Nobori, Haruaki: 1 article (12/2022)

Related Diseases

1.	COVID-19 02/22/2023 - "While phase 2 studies of ensitrelvir have demonstrated promising results in treating mild-to-moderate COVID-19, evaluation of its clinical efficacy due to shifting vaccination status and emergence of the Omicron variant represents significant challenges. " 04/26/2023 - "This practical process for manufacturing Ensitrelvir should contribute to protection against COVID-19." 02/22/2023 - "Through this study, we intend to validate and establish the efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19." 02/22/2023 - "In a post hoc analysis of the phase 2b study, compared with placebo, ensitrelvir demonstrated a reduced time to resolution of 5 symptoms in patients with mild-to-moderate COVID-19. " 02/22/2023 - "Here, we describe the protocol for a phase 3 study designed to evaluate the efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19, regardless of risk status or vaccination history. "
2.	Body Weight (Weight, Body) 10/28/2022 - "Body weight loss, survival, lung weight, cytokine/chemokine production, nucleocapsid protein expression and lung pathology were evaluated to investigate the in vivo efficacy of ensitrelvir. "
3.	Breast Neoplasms (Breast Cancer) 09/23/2023 - "Here, we determined the CP-I concentrations in a cocktail drug-drug interaction (DDI) study of ensitrelvir to evaluate the OATP1B inhibitory potential because ensitrelvir had increased plasma concentrations of rosuvastatin in this study, raising concerns about breast cancer resistance protein and OATP1B inhibition. "
4.	Infections 10/05/2023 - "SARS-CoV-2 gamma-strain-infected BALB/c mice were orally treated with various doses of ensitrelvir starting 24 h post-infection. " 10/28/2022 - "Female BALB/cAJcl mice of different ages were infected with the SARS-CoV-2 gamma strain (hCoV-19/Japan/TY7-501/2021) or mouse-adapted SARS-CoV-2 MA-P10 and then 24 h post-infection orally administered various doses of ensitrelvir or vehicle. " 02/14/2023 - "Moreover, the idealistic druglikeness and pharmacokinetic characteristics of S-217622 make it ready for pharmaceutical formulation with the expected very good clinical behavior as a drug for the infections caused by coronaviruses, e.g., COVID-19. " 12/01/2022 - "Ensitrelvir demonstrates strong in vitro antiviral activity against the SARS-CoV-2 Omicron subvariants BA.4 and BA.5, which have driven new waves of infection throughout 2022, suggesting a potential therapeutic option for patients with COVID-19. "
5.	Virus Diseases (Viral Diseases) 01/01/2023 - "The clinically approved drug nirmatrelvir and the clinical candidate ensitrelvir have so far showed great potential for treatment of viral infection. "

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	Nucleocapsid Proteins
3.	Chemokines
4.	Cytokines
5.	SARS-CoV-2 3C-like proteinase
6.	Protease Inhibitors (Protease Inhibitor)
7.	Triazoles
8.	fumaric acid (sodium fumarate)
9.	Suspensions
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Oral Administration